The Consent Premium: London Mid-Caps and the Cost of Raising Capital Without a Rights Issue

Rights issues are one of the City’s older rituals, and one of its more demanding. A company that asks existing shareholders to fund a recapitalisation must produce a circular, convene a general meeting, allow the shares to trade ex-rights and arrange underwriting that shifts risk onto banks and sub-underwriters. For a well-flagged raise with a supportive register, the process can be orderly. For a mid-cap facing a sudden refinancing need, a contested story or a narrow window of market calm, it can be slow, costly and uncertain.

That is why so many London-listed companies have come to prefer placings and accelerated bookbuilds. A placing can be priced overnight and settled before the market has had time to absorb the dilution. It is a pragmatic response to a real problem: equity capital is not always available on the timetable that a balance sheet requires. But the shortcut has a price, and in 2026 that price is becoming easier to see.

The mechanics of consent

Pre-emption rights are not a technicality. They are a protection against the transfer of value from existing holders to new ones, and a check on how quickly a board can change the shape of the register. When a company disapplies those rights, it is asking shareholders to accept a narrower say over future fundraising. That consent is usually granted within limits—most commonly through annual authorities that follow the Pre-emption Group’s principles—but the grant is not unconditional. It rests on a presumption that the board will use the flexibility sparingly, for identifiable purposes and with a clear account of the dilution involved.

The governance question, therefore, is not whether placings are legitimate. They are. The question is whether the pattern of use matches the stated purpose. A placing to fund an approved acquisition, or to repair a balance sheet under time pressure, is easier to defend than a sequence of smaller, open-ended raises that steadily erode the register’s influence. Investors notice the difference, even when each individual resolution passes comfortably.

The price of speed

Speed has a price, and it is usually paid in the discount. A placing must be priced at a level that attracts buyers quickly, often at a discount to the prevailing market price. That discount is not simply a transaction cost; it is a signal. It tells the market that the company needed capital more urgently than it needed to protect the value of its existing shares. In a calm market, a modest discount can be absorbed. In a more selective market, the discount widens, and the message becomes harder to manage.

For mid-caps, the effect can be amplified by liquidity. A FTSE 250 company with a concentrated institutional register may be able to place shares quickly, but the same concentration can make the subsequent overhang more visible. If the placing is followed by a period of weak performance, the shareholders who were not invited to participate are left with both dilution and a valuation mark. That combination tends to make the next request for disapplication more difficult.

The rights-issue machinery

None of this means the rights issue is broken. It remains the cleanest way to raise a large amount of equity from an existing register, and it gives shareholders the choice to follow their entitlement or to sell it. For companies with a broad retail base, a rights issue can also be a useful demonstration of fairness: everyone is treated according to the size of their holding, and the dilution is transparent.

But the machinery is ill-suited to certain situations. A rights issue takes weeks, not hours. It requires underwriting, which carries a cost and a risk. It can be difficult to execute when volatility is high or when the shareholder base includes many holders who may not take up their entitlements. The rump—the shares left with the underwriter—can become a market overhang in its own right.

The City has adapted by combining structures. A placing followed by an open offer, or a firm placing with an accompanying offer, can soften the dilution and give retail investors a route in. These structures are more flexible than a pure rights issue, but they are also more complex. They can blur the line between pre-emptive and non-pre-emptive capital, and they place a premium on clear disclosure. Investors need to understand not just what is being raised, but who is being invited to participate and on what terms.

What it means for 2026

UK mid-caps enter 2026 with a familiar set of pressures: refinancing needs, selective credit conditions and a shareholder base that is more attentive to capital allocation than it was during the easy-money years. The choice between a rights issue and a placing is therefore more than a technical decision. It is a test of capital strategy.

Companies that rely on placings should expect greater scrutiny of their use of proceeds, their discount discipline and their willingness to offer follow-on participation. Investors will look at whether the raise was genuinely time-critical, whether the board explored a pre-emptive structure, and whether the dilution was proportionate to the opportunity. A company that can answer those questions convincingly may find that the consent premium is manageable. A company that cannot may find that the next raise is harder to sell.

The rights issue is not dead, but it is no longer the default. The consent premium is real, and in 2026 London mid-caps will pay it either in time or in dilution. The better outcome is to choose consciously—and to explain the choice to the register before the market forces the issue.